Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy

Wei, Shanshan; Hu, Wenwei; Feng, Jun; Geng, Yiting

doi:10.1186/s12964-022-00960-x

Cited by 12 publications

(9 citation statements)

References 195 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…41 A series of investigations in the field revealed the extensive implication of microRNAs in regulation of EGFR signaling that significantly enhanced our detailed understanding of intestinal carcinogenesis. 42 Two of the most important EGFR-related microRNA tumor-suppressor genes are mir-143 and mir-145. Expression analyses have shown that these molecules are significantly diminished in cells of colorectal tumor origin compared with normal epithelium.…”

Section: Discussionmentioning

confidence: 99%

The Clinical Significance of MicroRNAs in Colorectal Cancer Signaling Pathways: A Review

Michas,

Anagnostou

et al. 2023

Glob Med Genet

View full text Add to dashboard Cite

Colorectal carcinoma (colon and rectum) is currently considered among the most prevalent malignancies of Western societies. The pathogenesis and etiological mechanisms underlying colorectal cancer (CRC) development remain complex and heterogeneous. The homeostasis and function of normal human intestinal cells is highly regulated by microRNAs. Therefore, it is not surprising that mutations and inactivation of these molecules appear to be linked with progression of colorectal tumors. Recent studies have reported significant alterations of microRNA expression in adenomas and CRCs compared with adjacent normal tissues. This observed deviation has been proposed to correlate with the progression and survival of disease as well as with choice of optimal treatment and drug resistance. MicroRNAs can adopt either oncogenic or tumor-suppressive roles during regulation of pathways that drive carcinogenesis. Typically, oncogenic microRNAs termed oncomirs, target and silence endogenous tumor-suppressor genes. On the other hand, tumor-suppressive microRNAs are critical in downregulating genes associated with cell growth and malignant capabilities. By extensively evaluating robust studies, we have emphasized and distinguished a discrete set of microRNAs that can modulate tumor progression by silencing specific driver genes crucial in signaling pathways including Wnt/b-catenin, epidermal growth factor receptor, P53, mismatch repair DNA repair, and transforming-growth factor beta.

show abstract

Section: Discussionmentioning

confidence: 99%

The Clinical Significance of MicroRNAs in Colorectal Cancer Signaling Pathways: A Review

Michas,

Anagnostou

et al. 2023

Glob Med Genet

View full text Add to dashboard Cite

show abstract

“…Recent studies have described the effects of non-coding RNAs on drug resistance in colorectal and lung cancer, including lncRNA, miRNA, and circRNAs, indicating that ncRNAs can be used as biomarkers to predict drug resistance. [97][98][99] Fatemeh Najafi et al also focused on the involvement of miR-424 and miR-631 in the regulation of tumor resistance and sensitivity. 100 EMT is an important mechanism by which tumors develop drug resistance, and HaShem khanbabaei et al summarized the relationship between non-coding RNAs and EMT in cancers, suggesting that ncRNAs might serve as important regulators in tumor resistance.…”

Section: Non-coding Rna and Drug Resistancementioning

confidence: 99%

Targeting epigenetic regulators to overcome drug resistance in cancers

Wang

2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

Drug resistance is mainly responsible for cancer recurrence and poor prognosis. Epigenetic regulation is a heritable change in gene expressions independent of nucleotide sequence changes. As the common epigenetic regulation mechanisms, DNA methylation, histone modification, and non-coding RNA regulation have been well studied. Increasing evidence has shown that aberrant epigenetic regulations contribute to tumor resistance. Therefore, targeting epigenetic regulators represents an effective strategy to reverse drug resistance. In this review, we mainly summarize the roles of epigenetic regulation in tumor resistance. In addition, as the essential factors for epigenetic modifications, histone demethylases mediate the histone or genomic DNA modifications. Herein, we comprehensively describe the functions of the histone demethylase family including the lysine-specific demethylase family, the Jumonji C-domain-containing demethylase family, and the histone arginine demethylase family, and fully discuss their regulatory mechanisms related to cancer drug resistance. In addition, therapeutic strategies, including small-molecule inhibitors and small interfering RNA targeting histone demethylases to overcome drug resistance, are also described.

show abstract

“…that may regulate genes primarily enriched in the Rap1 and RAS signaling pathways and result in a poorer prognosis. Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (cetuximab and panitumumab) are important for patients with wildtype RAS and BRAF metastatic CRC, high expression of lncRNAs (MIR100HG, UCA1, CRART16, SLCO4A1-AS1 and TTN-AS1) in CRC enhances the sensitivity of CRC cells to cetuximab and panitumumab [108].…”

Section: Lncrnas With Consensus Molecular Subgroupsmentioning

confidence: 99%

Long non-coding RNA signature in colorectal cancer: research progression and clinical application

2023

Cancer Cell Int

View full text Add to dashboard Cite

Colorectal cancer is one of the top-ranked human malignancies. The development and progression of colorectal cancer are associated with aberrant expression of multiple coding and non-coding genes. Long non-coding RNAs (lncRNAs) have an important role in regulating gene stability as well as gene expression. Numerous current studies have shown that lncRNAs are promising biomarkers and therapeutic targets for colorectal cancer. In this review, we have searched the available literature to list lncRNAs involved in the pathogenesis and regulation of colorectal cancer. We focus on the role of lncRNAs in cancer promotion or suppression, their value in tumor diagnosis, and their role in treatment response and prognosis prediction. In addition, we will discuss the signaling pathways that these lncRNAs are mainly associated with in colorectal cancer. We also summarize the role of lncRNAs in colorectal precancerous lesions and colorectal cancer consensus molecular subgroups. We hope this review article will bring you the latest research progress and outlook on lncRNAs in colorectal cancer.

show abstract

Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy

Cited by 12 publications

References 195 publications

The Clinical Significance of MicroRNAs in Colorectal Cancer Signaling Pathways: A Review

The Clinical Significance of MicroRNAs in Colorectal Cancer Signaling Pathways: A Review

Targeting epigenetic regulators to overcome drug resistance in cancers

Long non-coding RNA signature in colorectal cancer: research progression and clinical application

Contact Info

Product

Resources

About